Supriya Lifescience announced robust growth plans during a recent conference call. The company's formulation facility is expected to generate ₹450-500 crore in revenue. They maintained a 20% annual revenue growth guidance with EBITDA margins of 33-35%. A mid-term goal of ₹1,000 crore revenue by FY2027 was set. The company anticipates stronger volume growth over the next two years, driven by full capacity utilization of Module E by FY27 and launch of new products with significant global volume potential.
Supriya Lifescience Ltd. has released its Q4 financial results, showing significant year-over-year growth. Revenue increased by 16.46% to ₹1,840.00 million, EBITDA rose by 21.80% to ₹676.00 million, and net profit surged by 36.59% to ₹504.00 million. The company's EBITDA margin expanded to 36.72% from 35.09% in the previous year. Quarter-on-quarter growth was also notable, with net profit increasing by 7.69%. The board has recommended a dividend of ₹1.00 per equity share.